FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 646 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... May 10, 2019 Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... December 12, 2019 Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma March 30, 2022 Load more HOT NEWS Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... The Horror Story Of What Can Happen When You Don’t Pay... FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC... Childhood cancer survivors at greater risk of ill health
